Comparison · NCT00148733-ba1110e1
Zinc vs Placebo: Risk of Treatment Failure.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Zinc vs Placebo: Risk of Treatment Failure. Trial comparisons, record NCT00148733-ba1110e1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00148733-ba1110e1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.205 | 0.184 | 0.228 | wilson | |
| Risk in group 2 | 0.195 | 0.174 | 0.217 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0106 | -0.0202 | 0.0414 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.904 | 1.23 | log | |
| Odds ratio, group 1 over group 2 | 1.07 | 0.882 | 1.3 | log | |
| Number needed to treat, for one more participant with the outcome on Zinc than on Placebo | 94.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Zinc | Zinc sulphate 10 or 20 mg (elemental zinc) per day. Intervention and placebo given perorally mixed with approximately 5 mL of breastmilk or clean water~Zinc: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months | 267 | 1,300 | OG000 |
| Group 2 | Placebo | Placebo~Zinc: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months | 253 | 1,299 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Risk of Treatment Failure.
- Description
- Enrolled children will be followed and given zinc or placebo for 14 days. We will compare the proportion with treatment failure (i.e. lack of improvement within 3 days) between the two groups
- Time frame
- Within 2 weeks after enrollment
- Population
Source ClinicalTrials.gov
Trial
- Title
- CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia
- NCT number
- NCT00148733
- Phases
- PHASE2, PHASE3
- Conditions
- Pneumonia
- Interventions
- Zinc
- Lead sponsor
- Centre For International Health
- Results first posted
- 2015-02-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00148733?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00148733-ba1110e1